Dynavax Technologies (NASDAQ:DVAX) Share Price Passes Above 200-Day Moving Average – What’s Next?

Shares of Dynavax Technologies Co. (NASDAQ:DVAX) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.62 and traded as high as $12.87. Dynavax Technologies shares last traded at $12.62, with a volume of 5,449,688 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Trading Up 0.1 %

The stock has a fifty day simple moving average of $12.74 and a 200 day simple moving average of $11.63. The firm has a market capitalization of $1.66 billion, a P/E ratio of 97.16 and a beta of 1.34. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Institutional Investors Weigh In On Dynavax Technologies

A number of institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Dynavax Technologies during the third quarter valued at about $45,000. Nisa Investment Advisors LLC increased its holdings in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Dynavax Technologies in the third quarter worth about $89,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.